Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
This issue brief is the fifth in a series produced by MSF to equip policymakers, people living with HIV/AIDS, and communities with information on the products, costs, and operational strategies to help realise scale-up of viral load monitoring, which we believe is an essential tool, along with adherence support, to help as many people on ART as possible to reach and maintain viral suppression. DOWNLOAD THE BRIEFING DOCUMENT
In many places, you can often arrive at a health centre – a place that should be buzzing with children – to find it is totally empty, no staff or anything. You understand why when you see that the fridge to store the vaccines is broken and no child has been vaccinated in months. DOWNLOAD English
Last updated 16 April 2014
The new face of an old disease: urgent action needed to tackle global drug-resistant TB threat March
Last updated 17 March 2014
Submission to the Expert Committee on “Regulation of Newer TB drugs in India”, Ministry of Health & Family Welfare, January 2014
Last updated 6 March 2014
Pricing for HIV viral load testing in low- and middle-income countries
Last updated 6 December 2013
Four essential interventions to improve HIV treatment, save lives and reduce transmission Today, nearly ten million people are receiving antiretroviral therapy (ART) in developing countries, but with an estimated additional 18 million people1 eligible for treatment, the job is far from done. With the release of new ART guidelines in 2013,2 the World Health Organization (WHO) has laid out a clear benchmark for the quality of care that national treatment programmes, treatment providers and donors should strive to achieve.
Last updated 6 December 2013
The Open Source Fever Diagnostic Project The World Health Organization (WHO), as part of its broader efforts to address health R&D gaps for the poor, is conducting a process whereby member states will support "health R&D demonstration projects" aimed at developing health technologies (medicines, diagnostics, medical devices, vaccines, etc.) for diseases that disproportionately affect developing countries and for which identified R&D gaps remain unaddressed due to market failures.
Last updated 25 November 2013
Tuberculosis (TB) mainly affects low- and middle- income countries with 95% of cases occurring there. 1.3 million people were killed by the disease in 2012 and there were 8.6 million new cases requiring treatment. With the advent of new diagnostics like GeneXpert the confirmed numbers of multidrug-resistant (MDR) TB cases are rising and programmes are unable to cope - 16,000 patients diagnosed with MDR-TB in 2012 did not receive treatment. And about 80% of those estimated to have MDR-TB are not even diagnosed.
Last updated 7 November 2013
Last updated 26 October 2013
Each year, the lives of two and a half million children are saved because they are protected against killer diseases through vaccination. Vaccinating with new vaccines should save many more lives, but high prices could prevent this from happening.
Last updated 15 October 2013